We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Characterizing Cognitive Decline in Late Life Depression: The ADNI Depression Project (ADNI-D)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02434393
Recruitment Status : Active, not recruiting
First Posted : May 5, 2015
Last Update Posted : October 21, 2022
National Institute of Mental Health (NIMH)
University of California, San Francisco
Alzheimer's Therapeutic Research Institute
Information provided by (Responsible Party):
Paul Aisen, University of Southern California

Brief Summary:

The purpose of this research study is to characterize the mechanisms contributing to cognitive impairment and accelerated cognitive decline in Late Life Depression (LLD).

This is a non-randomized, observational, non-treatment study. One hundred and twenty (120) subjects who meet criteria for Major Depression or LLD will be enrolled for a period of 30 months. Data from an additional 300 non-depressed subjects will be used from ADNI studies for comparison.

Depression history, symptom severity and health information will be collected at the initial psychiatric visit to determine eligibility. A 3 Tesla (3T) Magnetic resonance imaging (MRI) scan and florbetapir (18F-AV-45) amyloid imaging will be conducted at the ADNI clinic site visits. Collection of plasma and serum for biomarkers, clinical assessments and cognitive assessments will be conducted at two time points. Blood samples will also be collected for genetic analysis.

Condition or disease
Major Depression Late Life Depression (LLD)

Layout table for study information
Study Type : Observational
Actual Enrollment : 133 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Characterizing Cognitive Decline in Late Life Depression: The Alzheimer's Disease Neuroimaging Initiative - Depression Project
Actual Study Start Date : March 4, 2015
Estimated Primary Completion Date : May 2027
Estimated Study Completion Date : May 2027

Resource links provided by the National Library of Medicine

Late Life Depression
120 participants who meet the criteria for Major Depression or Late Life Depression (LLD)

Primary Outcome Measures :
  1. Rate of Change in neuropsychological measures of executive function as measured by the Digit Symbol Substitution Test using total correct. [ Time Frame: 5 years ]
    The Digit Symbol subtest is a measure of attention, working memory, and information processing speed. Participants are presented with a stimulus sheet, and asked to write in the correct symbol that corresponds with a number keyed at the top of the page. A scaled score is calculated based on the number of total correct responses.

  2. Rate of Change in expressive language as measured by the Boston Naming Test using total correct. [ Time Frame: 5 years ]
    Boston Naming Test is a measure of visual confrontation naming requires the subject to name objects depicted in outline drawings. The drawings are graded in difficulty, with the easiest drawings presented first. If a subject encounters difficulty in naming an object, a stimulus cue and/or a phonemic cue is provided. The number of spontaneous correct responses (maximum score = 30) and spontaneous plus semantically-cued correct responses (maximum score = 30) are recorded. The number of perceptual errors, circumlocutions, paraphasic errors, and perseverations can also be used to evaluate the subjects' language performance.

  3. Rate of change in learning and memory as measured by the Rey Auditory Verbal Learning Test using total correct and delayed recall. [ Time Frame: 5 years ]
    Rey Auditory Verbal Learning Test (AVLT) is a list learning task which assesses multiple cognitive parameters associated with learning and memory. On each of 5 learning trials, 15 unrelated words (all nouns) are presented orally at the rate of one word per second and immediate free recall of the words is elicited. The number of correctly recalled words on each trial is recorded. Following a 20-minute delay filled with unrelated testing, free recall of the original 15 word list is elicited. Finally, a yes/no recognition test is administered which consists of the original 15 words and 15 randomly interspersed distracter words. The number of target "hits" and false positive responses are recorded.

  4. Change in brain structure using magnetic resonance imaging (MRI) [ Time Frame: 2.5 years ]
    MRI will be used to conduct cortical thickness analysis of whole brain and hippocampus utilizing the following sequences: 3D T1-weighted volume, FLAIR, T2*GRE, and Arterial Spin-Labeling (ASL) Perfusion.

  5. Extent of amyloid deposition as measured by Florbetapir F 18: Datum of these scans will be collected via standardized uptake value ratios (SUVR) normalized to the cerebellum [ Time Frame: 2.5 years ]

Secondary Outcome Measures :
  1. Use biomarkers data employed in ADNI-2 and the NIA AD (Alzheimer's Disease) Genetics Consortium to determine the genotypes needed for the genome wide association study (GWAS). [ Time Frame: 2.5 years ]
    Data from participants will be entered into the NIH Genome-Wide database and made available to the scientific community.

Biospecimen Retention:   Samples With DNA
blood, urine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
120 older adults meeting criteria for Major Depression or Late Life Depression (LLD).

Inclusion Criteria:

  1. Current DSM-IV diagnosis of Major Depressive Disorder, unipolar type, without psychotic features and six week minimum duration of current depressive episode.
  2. English Speaking
  3. 65+ years of age
  4. Hamilton Depression Rating Scale score ≥ 15
  5. Able to give informed consent
  6. Willing to undergo one MRI (3 Tesla) and one PET scan (Amyloid imaging)
  7. Able to fit in an MRI machine comfortably (BMI ≤ 38)
  8. Agrees to collection of blood for GWAS, apolipoprotein E (APOE) testing and DNA and RNA testing
  9. Agrees to collection of blood for biomarker testing
  10. Agrees to collection of additional blood sample for to-be-determined assays and telomere length measurement
  11. Visual and auditory acuity adequate for neuropsychological testing
  12. Completed six grades of education or has established work history (sufficient to exclude mental retardation)
  13. Study partner is available who has frequent contact with the subject (e.g. an average of 10 hours per week or more), and can accompany the subject to clinical visits for the duration of the protocol.

Exclusion Criteria:

  1. Current diagnosis of other axis 1 psychiatric disorders (with the exception of Simple Phobias and Generalized Anxiety Disorder)
  2. Evidence of Dementia (MMSE <25)
  3. Any electroconvulsive therapy within the past 6 months
  4. Undergoing anti-depressant or psychotherapy treatment (exceptions listed 4.3. Treatment Exclusion Exceptions)
  5. Any significant neurological diseases (i.e. Parkinson's disease, epilepsy, cortical stroke, traumatic brain injury)
  6. History of alcohol or substance abuse or dependence within the past 2 years (DSM-IV criteria)
  7. Any active and serious suicidal ideation, including ideation, plan and intent to carry out that plan, as assessed by the Hamilton Depression Rating Scale (HDRS)
  8. Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol
  9. History of surgical procedures effecting study outcomes
  10. Residence in skilled nursing facility
  11. Participation in clinical studies involving the same neuropsychological measures used in ADNI-D that may impact study outcomes
  12. Investigational agents are prohibited one month prior to entry and for the duration of the trial
  13. Exclusion for amyloid imaging with florbetapir: Current or recent participation in any procedures involving radioactive agents such that the total radiation dose exposure to the subject in any given year would exceed the limits of annual and total dose commitment set forth in the US Code of Federal Regulations (CFR) Title 21 Section 361.1
  14. Known history of MRI scans with evidence of infection, infarction, or other focal lesions. Subjects with multiple lacunes or lacunes in a critical memory structure are excluded
  15. Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body, claustrophobia
  16. Pregnant, lactating, or of childbearing potential (i.e. women must be two years post-menopausal or surgically sterile)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02434393

Layout table for location information
United States, California
University of California, San Francisco
San Francisco, California, United States, 94143
United States, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
University of Southern California
National Institute of Mental Health (NIMH)
University of California, San Francisco
Alzheimer's Therapeutic Research Institute
Layout table for investigator information
Study Director: Rema Raman, PhD USC Alzheimer's Therapeutic Research Institute
Study Director: Scott Mackin, PhD University of California, San Francisco
Additional Information:
Layout table for additonal information
Responsible Party: Paul Aisen, Professor, University of Southern California
ClinicalTrials.gov Identifier: NCT02434393    
Other Study ID Numbers: ADC-048
R01MH098062 ( U.S. NIH Grant/Contract )
First Posted: May 5, 2015    Key Record Dates
Last Update Posted: October 21, 2022
Last Verified: October 2022
Keywords provided by Paul Aisen, University of Southern California:
Late Life Depression
amyloid imaging
Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Cognitive Dysfunction
Behavioral Symptoms
Mood Disorders
Mental Disorders
Cognition Disorders
Neurocognitive Disorders